Navigation Links
ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference
Date:5/4/2010

rop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='92776124';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.chemocentryx.com/">www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implementation of ChemoCentryx's business model, strategic plans for its business, product candidates and technology, (vi) ChemoCentryx's ability to maintain and establish collaborations or obtain additional government grant funding, (vii) ChemoCentryx's estimates of its expenses, future revenues, capital requirements and its needs for additional financing, (viii) the timing or likelihood of regulatory filings and approvals, (ix) the
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 28, 2015 Anteo Technologies is transforming ... tools developed with their patented Mix&Go™ Activation Reagent. ... helping to improve medical devices and in-vitro diagnostics, ... Increasingly complex multifactorial diagnosis of cancer and autoimmune ... is restricted to measure only a single ...
(Date:4/27/2015)... -- Techpool Bio-Pharma Co has experienced tremendous changes in the ... executive officer, transforming from a traditional private Chinese company to ... took office in 2011, he was the senior executive in ... Eisai, with more than 20 years successful management experience in ... Asia-Pacific region. "I chose Techpool because ...
(Date:4/27/2015)... 2015   Intarcia Therapeutics, Inc. today announced ... with an equity conversion option at a $5.5 billion ... accelerate the initiation of additional head-to-head comparative and switch ... type 2 diabetes therapies. In addition, proceeds from the ... to launch ITCA 650 in the United ...
Breaking Medicine Technology:Faster Detection of Disease: Anteo is Transforming The Way Scientists Work with Luminex(R) xMAP(R) 2Faster Detection of Disease: Anteo is Transforming The Way Scientists Work with Luminex(R) xMAP(R) 3Techpool Transforms Into International Player 2Techpool Transforms Into International Player 3Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation 2Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation 3
... company products from its distribution operations in Enfield, Connecticut on Sunday, March 14 .   , ... , , ... ... Lilly is working with the U.S. ...
... The latest advancement in facial contouring, the AccuLift™ procedure, was just featured on CBS, The Early Show .  New York physician Dr. Jon Turk ... ... , ... ...
Cached Medicine Technology:Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 2Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 3Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 4Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 5Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 6Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 7Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 8'The AccuLift Phenomenon' Kicks off on CBS' The Early Show 2'The AccuLift Phenomenon' Kicks off on CBS' The Early Show 3
(Date:4/28/2015)... (PRWEB) April 28, 2015 MSA ... healthcare executive search, announced today that it has been ... Chief Operating Officer search for The Queen's ... , Reporting to QHS President & CEO Arthur A. ... will have operating responsibility for the Queen’s Medical Center ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 New ... also require more of manufacturers, payers, pharmacists and ... field’s premier journal, is partnering with the National ... trade association dedicated solely to this developing field ... fill this growing need. , “This partnership creates ...
(Date:4/28/2015)... Hellen Chen, who is a bestselling author ... According to a study conducted by Washington University, ... 30 has increased by 20% while the number of unfaithful ... a report released this year from the Journal ... one or both spouses admit to infidelity, either physical or ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 The buyer ... 2.9 out of 5, indicating a medium level of ... buyers and suppliers have equal power during negotiations. One ... Rather than purchasing a health insurance policy from an ... or Humana), buyers can choose to self-fund their own ...
(Date:4/28/2015)... OsteoRemedies®, LLC, Memphis, TN, offers the ... infected hip and knee arthroplasty. , ... pre-loaded spacer with Gentamicin Antibiotics, for consistent and ... Combined with a consistent process for polishing the ... for temporary use for up to 180 days. ...
Breaking Medicine News(10 mins):Health News:The Queen’s Health Systems Retains MSA Executive Search to Recruit Executive Vice President & Chief Operating Officer 2Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 2Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 3Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 4Health News:Why Do Some Good Women and Men End Up Breaking Others' Marriages? 2Health News:Why Do Some Good Women and Men End Up Breaking Others' Marriages? 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 4
... Research to Replicate Insulin-Producing Function of Healthy Pancreas for ... Calif., March 31 A key step toward the ... diabetes has been achieved, according to new research published ... Therapeutics .Researchers at the University of California at ...
... Md., March 31 John Lawson Cullison, Jr., an artist ... or "new age art," lost his ability to paint due ... due to the degeneration in cartilage tissue and symptoms include: ... spurs and severe swelling. Pain management and joint replacement ...
... refractory patients recruited in trial;, ... complete efficacy data to be available in ... Life Sciences Inc. (TSX: BNC), a research-based, technology-driven ... completed recruitment in its initial Phase III registration ...
... Available for Women Suffering from InsomniaLOS ANGELES, March 31 ... more lasting and negative impact than a lost night,s ... take care of and the endless array of other ... afford to lose any sleep.(Photo: http://www.newscom.com/cgi-bin/prnh/20090331/NYFNSS01 )Unfortunately, ...
... in The Journal of Nursing Administration shows ... continuous vigilance monitoring is used on medical-surgical unit beds. ... President and CEO of Hoana Medical, Inc. "Using ... potential patient deterioration so they can respond appropriately. ...
... Provides Extensive Services & SupportSAN FRANCISCO, March 31 ... home support and recovery services has announced a new ... HomeStyle Services first opened its San Francisco office in ... people remain independent as they age or recover from ...
Cached Medicine News:Health News:Researchers Successfully Create Computer-Simulated Model for Evaluating Artificial Pancreas 2Health News:Researchers Successfully Create Computer-Simulated Model for Evaluating Artificial Pancreas 3Health News:Korean Stem Cells Allow Artist to Paint Again 2Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 2Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 3Health News:Tired of Sleepless Nights? 2Health News:Continuous Vigilance Monitoring Technology Benefits Nurses & Patients 2Health News:Nation's Largest Home Care Provider Welcomes New Management Team to San Francisco Office 2
Blunt cannula for injection or aspiration of fluid. Thinwall cannula allows high flow rate. Blunt tip is smooth all around for easy insertion. Luer lock hub for easy, secure connection to a backflus...
PLX Series Sealed CO2 OEM Lasers....
... cost-effective line of compact CO2 systems combines ... an extremely accurate laser beam, as well ... especially advantageous for small operating theatres and ... Use of special contact tips and accessories ...
... NovaPulse 20-watt CO2 laser is ideal for ... flexible fiber delivery system, it combines the ... a familiar scalpel-like feel. The Novapulse system ... short pauses during which tissue is allowed ...
Medicine Products: